Cout de la Prise en Charge du Cancer Colorectal au Niveau de lEPH IBN SINA (Oum El Bouaghi)

Abstract

The fight against colorectal cancer has progressed in recent years, thanks to the addition to chemotherapy of targeted therapies against angiogenesis factors (bevacizumab) or tumor growth factor receptors (cetuximab and panitumumab). These targeted therapies have proven their effectiveness but they nevertheless remain expensive molecules; their high cost prompted us to conduct a study to evaluate the cost of treatment. The objective assigned to this work is to evaluate the costs generated by the hospital care of patients with colorectal cancer at the level of LEPH IBNSINA of the wilaya of oum el bouaghi. To do this, we proceeded by field study through the examination of all the medical records of patients treated in the hospital (23 patients) for the period from 2023 to 2024. The cost of colorectal cancer treatments is 18027495.66 DA for the study period. Thus, the average cost of surgery for each patient is 60034.56 DA. Cost assessment showed that there is a positive correlation between the stage of the disease, the number of chemotherapy sessions and the choice of the targeted CRC therapy molecule and the cost of care. Consequently, the latter can decrease significantly if the cancer is treated at an early stage. The use of targeted therapies in the treatment of CCRM has generated significant costs at the cost of an increase in survival of a few months, due to a lack of data, it was difficult for us to draw a conclusion on the results.